Findings

What do systematic reviews say?

4,808 questions · 8,953 findings · 827 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,891 · 21.1%GRADE not reported 380 · 4.2%Very low 2,100 · 23.5%Low 2,449 · 27.4%Moderate 1,684 · 18.8%High 449 · 5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Mirror therapy vs other interventions

Motor impairment at the end of intervention phase: all outcome measures

1 finding from 1 review

Mirror therapy for improving motor function after stroke 2018 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 1292 participants
Moderate

Mirror therapy vs other interventions

Secondary outcome measure: mean upper extremity function at the end of the intervention periodClinical measures of upper extremity function. Scale from: 0 to infinity.

1 finding from 1 review

Mirror therapy for improving motor function after stroke 2018 · Cochrane Headline outcomes only
no estimate extracted
28 studies · 898 participants
Low

Mirror therapy vs other interventions

Activities of daily living

1 finding from 1 review

Mirror therapy for improving motor function after stroke 2018 · Cochrane Headline outcomes only
no estimate extracted
19 studies · 622 participants
Moderate

Mirror therapy vs other interventions

Pain at the end of intervention phase: all studies

1 finding from 1 review

Mirror therapy for improving motor function after stroke 2018 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 248 participants
Low

Mirror therapy vs other interventions

Pain at the end of intervention phase after excluding studies with CRPS

1 finding from 1 review

Mirror therapy for improving motor function after stroke 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 176 participants
Moderate

Mirror therapy vs other interventions

Visuospatial neglect at the end of intervention: all studies

1 finding from 1 review

Mirror therapy for improving motor function after stroke 2018 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 175 participants
Low

Neoadjuvant chemotherapy prior to interval surgery (NACT) vs surgery followed by chemotherapy (PDS)

Overall survival ( · women with advanced ovarian epithelial cancer

Neoadjuvant chemotherapy prior to interval surgery (NACT) showed no clear difference in overall survival ( compared with surgery followed by chemotherapy (PDS) (high certainty).

1 finding from 1 review

Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced… 2021 · Cochrane Headline outcomes only
HR 0.96 [0.86, 1.08]
4 studies · 2000 participants
High

Neoadjuvant chemotherapy prior to interval surgery (NACT) vs surgery followed by chemotherapy (PDS)

Progression‐free survival · women with advanced ovarian epithelial cancer

Neoadjuvant chemotherapy prior to interval surgery (NACT) showed no clear difference in progression‐free survival ( compared with surgery followed by chemotherapy (PDS) (moderate certainty).

1 finding from 1 review

Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced… 2021 · Cochrane Headline outcomes only
HR 0.98 [0.88, 1.08]
4 studies · 1847 participants
Moderate

Neoadjuvant chemotherapy prior to interval surgery (NACT) vs surgery followed by chemotherapy (PDS)

Surgically‐related severe adverse effects (grade 3+) ‐ stoma formation (within 30 days of surgery) · women with advanced ovarian epithelial cancer

Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ stoma… compared with surgery followed by chemotherapy (PDS) (moderate certainty).

1 finding from 1 review

Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced… 2021 · Cochrane Headline outcomes only
RR 0.29 [0.12, 0.74]
2 studies · 632 participants
Moderate

Neoadjuvant chemotherapy prior to interval surgery (NACT) vs surgery followed by chemotherapy (PDS)

Surgically‐related severe adverse effects (grade 3+) ‐ bowel resection (within 30 days of surgery) · women with advanced ovarian epithelial cancer

Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ bowel… compared with surgery followed by chemotherapy (PDS) (moderate certainty).

1 finding from 1 review

Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced… 2021 · Cochrane Headline outcomes only
RR 0.49 [0.3, 0.79]
4 studies · 1565 participants
Moderate

Neoadjuvant chemotherapy prior to interval surgery (NACT) vs surgery followed by chemotherapy (PDS)

Surgically‐related severe adverse effects (grade 3+) ‐ postoperative G3+ events (within 30 days of surgery) · women with advanced ovarian epithelial cancer

Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ postoperative… compared with surgery followed by chemotherapy (PDS) (moderate certainty).

1 finding from 1 review

Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced… 2021 · Cochrane Headline outcomes only
RR 0.22 [0.13, 0.38]
2 studies · 435 participants
Moderate

Neoadjuvant chemotherapy prior to interval surgery (NACT) vs surgery followed by chemotherapy (PDS)

Surgically‐related postoperative mortality (28 days to 6 months of surgery4) · women with advanced ovarian epithelial cancer

Neoadjuvant chemotherapy prior to interval surgery (NACT) leads to lower surgically‐related postoperative mortality (28 days to 6 months of… compared with surgery followed by chemotherapy (PDS) (high certainty).

1 finding from 1 review

Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced… 2021 · Cochrane Headline outcomes only
RR 0.16 [0.06, 0.46]
5 studies · 1623 participants
High

Neoadjuvant chemotherapy prior to interval surgery (NACT) vs surgery followed by chemotherapy (PDS)

EORTC QLQ‐C30 QoL at 6 months ‐ global health · women with advanced ovarian epithelial cancer

1 finding from 1 review

Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced… 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 524 participants
Very low

Sclerotherapy (STS) vs sclerotherapy (any sclerosant)

Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 473 participants
Moderate

Sclerotherapy (STS) vs sclerotherapy (any sclerosant)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Sclerotherapy (STS) probably leads to higher adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 1.71 [1.1, 2.64]
4 studies · 478 participants
Moderate

Sclerotherapy (STS) vs sclerotherapy (any sclerosant)

Adverse events ‐ matting ( · people with telangiectasias and reticular veins

Sclerotherapy (STS) probably leads to higher adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 2.1 [1.14, 3.85]
2 studies · 323 participants
Moderate

Sclerotherapy (STS) vs sclerotherapy (any sclerosant)

Pain ( · people with telangiectasias and reticular veins

Sclerotherapy (STS) showed no clear difference in pain ( compared with sclerotherapy (any sclerosant) (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 1.49 [0.99, 2.25]
4 studies · 409 participants
Moderate

Sclerotherapy (STS) vs sclerotherapy (any sclerosant)

Recurrence · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy (STS) vs sclerotherapy (any sclerosant)

Time to resolution · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy (STS) vs sclerotherapy (any sclerosant)

Quality of life · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found